Lv54
970 积分 2023-02-16 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
12小时前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
12小时前
已完结
Selective amylin receptor agonism: promise beyond incretins
12小时前
已完结
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
13小时前
已完结
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
13小时前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
1天前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
1天前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2天前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
2天前
已完结
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
2天前
已完结
皖公网安备34019202002308
